Spero Therapeutics SPRO

$ 1.18 -1.26%

Quarterly report 2024-Q3
added 11-14-2024

Spero Therapeutics Balance Sheet 2011-2024 | SPRO

Annual Balance Sheet Spero Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-70.8 M	-102 M	-105 M	-77.4 M	-24.2 M	-34.1 M	-87.3 M	-10.3 M	-5.69 M	-	-	-	-
Long Term Debt	3.82 M	4.96 M	5.97 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	1.72 M	1.69 M	1.36 M	947 K	928 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	7.07 M	4.87 M	833 K	365 K	493 K	1.01 M	-	-	-	-
Total Current Liabilities	37.2 M	21.6 M	18.7 M	14.3 M	26.7 M	12.3 M	8.16 M	-	-	-	-	-	-
Total Liabilities	75.5 M	48.9 M	82.8 M	21.4 M	31.5 M	13.2 M	8.52 M	7.41 M	7.43 M	-	-	-	-
Deferred Revenue	2.13 M	4.15 M	1.86 M	-	-	-	-	-	512 K	-	-	-	-
Retained Earnings	-391 M	-414 M	-367 M	-278 M	-199 M	-139 M	-96.8 M	-45.4 M	-18.1 M	-	-	-	-
Total Assets	182 M	125 M	171 M	153 M	106 M	129 M	93.5 M	13.8 M	7.18 M	-	-	-	-
Cash and Cash Equivalents	76.3 M	109 M	113 M	85.2 M	29.7 M	34.1 M	87.3 M	-	-	-	-	-	-
Book Value	107 M	75.9 M	88.3 M	132 M	74.6 M	116 M	85 M	6.36 M	-257 K	-	-	-	-
Total Shareholders Equity	107 M	75.9 M	88.3 M	132 M	74.6 M	116 M	84.6 M	-49.2 M	-18.6 M	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Spero Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	2.88 M	3.21 M	3.52 M	3.82 M	4.12 M	4.41 M	4.68 M	4.96 M	5.22 M	5.47 M	5.73 M	5.97 M	6.19 M	6.43 M	6.66 M	6.89 M	6.89 M	6.89 M	6.89 M	4.62 M	4.62 M	4.62 M	4.62 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	69.7 M	69.4 M	71.5 M	75.5 M	53.4 M	44.1 M	47.7 M	48.9 M	32 M	27.7 M	83.4 M	82.8 M	32.8 M	29.3 M	24.6 M	21.4 M	21.4 M	21.4 M	21.4 M	31.5 M	31.5 M	31.5 M	31.5 M	13.2 M	13.2 M	13.2 M	13.2 M	8.52 M	8.52 M	8.52 M	8.52 M	7.41 M	7.41 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	788 K	3.66 M	2.87 M	2.13 M	13.9 M	8.71 M	11.8 M	10.4 M	3.73 M	2.36 M	2.09 M	1.86 M	1.7 M	1.18 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-439 M	-422 M	-404 M	-391 M	-442 M	-439 M	-427 M	-414 M	-441 M	-429 M	-400 M	-367 M	-338 M	-316 M	-297 M	-278 M	-278 M	-278 M	-278 M	-199 M	-199 M	-199 M	-199 M	-139 M	-139 M	-139 M	-139 M	-96.8 M	-96.8 M	-96.8 M	-96.8 M	-45.4 M	-45.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	135 M	150 M	168 M	182 M	107 M	98.9 M	113 M	125 M	64.5 M	63.6 M	146 M	171 M	145 M	120 M	143 M	153 M	153 M	153 M	153 M	106 M	106 M	106 M	106 M	129 M	129 M	129 M	129 M	93.5 M	93.5 M	93.5 M	93.5 M	13.8 M	13.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	76.3 M	63.5 M	82.3 M	76.3 M	93.8 M	77.7 M	96.3 M	109 M	50.4 M	45.4 M	72.1 M	113 M	113 M	71.6 M	77 M	85.2 M	85.2 M	85.2 M	85.2 M	29.7 M	29.7 M	29.7 M	29.7 M	34.1 M	34.1 M	34.1 M	34.1 M	87.3 M	87.3 M	87.3 M	87.3 M	10.3 M	10.3 M	-	-	5.69 M	-	-	-	256 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	65.5 M	80.5 M	96.2 M	107 M	53.7 M	54.8 M	64.8 M	75.9 M	32.5 M	35.9 M	62.5 M	88.3 M	112 M	90.3 M	119 M	132 M	132 M	132 M	132 M	74.6 M	74.6 M	74.6 M	74.6 M	116 M	116 M	116 M	116 M	85 M	85 M	85 M	85 M	6.36 M	6.36 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	65.5 M	80.5 M	96.2 M	107 M	53.7 M	54.8 M	64.8 M	75.9 M	32.5 M	35.9 M	62.5 M	88.3 M	112 M	90.3 M	119 M	132 M	132 M	132 M	132 M	74.6 M	74.6 M	74.6 M	74.6 M	116 M	116 M	116 M	116 M	84.6 M	84.6 M	84.6 M	84.6 M	-45.4 M	-45.4 M	-	-	-18.6 M	-	-	-	-6.11 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency